TRML vs. KNSA, GPCR, NRIX, ARQT, ARDX, INDV, ARVN, VIR, SNDX, and ANIP
Should you be buying Tourmaline Bio stock or one of its competitors? The main competitors of Tourmaline Bio include Kiniksa Pharmaceuticals (KNSA), Structure Therapeutics (GPCR), Nurix Therapeutics (NRIX), Arcutis Biotherapeutics (ARQT), Ardelyx (ARDX), Indivior (INDV), Arvinas (ARVN), Vir Biotechnology (VIR), Syndax Pharmaceuticals (SNDX), and ANI Pharmaceuticals (ANIP). These companies are all part of the "pharmaceutical products" industry.
Tourmaline Bio vs.
Kiniksa Pharmaceuticals (NASDAQ:KNSA) and Tourmaline Bio (NASDAQ:TRML) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends and community ranking.
54.0% of Kiniksa Pharmaceuticals shares are owned by institutional investors. Comparatively, 91.9% of Tourmaline Bio shares are owned by institutional investors. 54.6% of Kiniksa Pharmaceuticals shares are owned by insiders. Comparatively, 11.0% of Tourmaline Bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Tourmaline Bio has a net margin of 0.00% compared to Kiniksa Pharmaceuticals' net margin of -2.36%. Kiniksa Pharmaceuticals' return on equity of -7.31% beat Tourmaline Bio's return on equity.
Kiniksa Pharmaceuticals has a beta of 0.32, suggesting that its share price is 68% less volatile than the S&P 500. Comparatively, Tourmaline Bio has a beta of 2.32, suggesting that its share price is 132% more volatile than the S&P 500.
Kiniksa Pharmaceuticals received 154 more outperform votes than Tourmaline Bio when rated by MarketBeat users. However, 100.00% of users gave Tourmaline Bio an outperform vote while only 65.02% of users gave Kiniksa Pharmaceuticals an outperform vote.
Kiniksa Pharmaceuticals currently has a consensus target price of $36.60, suggesting a potential upside of 82.97%. Tourmaline Bio has a consensus target price of $54.00, suggesting a potential upside of 341.50%. Given Tourmaline Bio's higher probable upside, analysts plainly believe Tourmaline Bio is more favorable than Kiniksa Pharmaceuticals.
Kiniksa Pharmaceuticals has higher revenue and earnings than Tourmaline Bio. Kiniksa Pharmaceuticals is trading at a lower price-to-earnings ratio than Tourmaline Bio, indicating that it is currently the more affordable of the two stocks.
In the previous week, Tourmaline Bio had 3 more articles in the media than Kiniksa Pharmaceuticals. MarketBeat recorded 5 mentions for Tourmaline Bio and 2 mentions for Kiniksa Pharmaceuticals. Tourmaline Bio's average media sentiment score of 0.59 beat Kiniksa Pharmaceuticals' score of 0.56 indicating that Tourmaline Bio is being referred to more favorably in the news media.
Summary
Tourmaline Bio beats Kiniksa Pharmaceuticals on 9 of the 16 factors compared between the two stocks.
Get Tourmaline Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for TRML and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Tourmaline Bio Competitors List
Related Companies and Tools
This page (NASDAQ:TRML) was last updated on 2/21/2025 by MarketBeat.com Staff
Free TRML Stock Alerts